Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9301456rdf:typepubmed:Citationlld:pubmed
pubmed-article:9301456lifeskim:mentionsumls-concept:C0029925lld:lifeskim
pubmed-article:9301456lifeskim:mentionsumls-concept:C0026882lld:lifeskim
pubmed-article:9301456lifeskim:mentionsumls-concept:C0079419lld:lifeskim
pubmed-article:9301456pubmed:issue8lld:pubmed
pubmed-article:9301456pubmed:dateCreated1997-10-8lld:pubmed
pubmed-article:9301456pubmed:abstractTextThis short report describes the detection of mutations of the TP53 tumour suppressor gene in sporadic ovarian carcinomas using archival paraffin-embedded tissues and automated fluorescent DNA sequencing. TP53 mutations were detected in eight tumours. Missense mutations predominated and all were transitions. Mutations were commonest in late-stage serous tumours. In three cases, where tissue was available, the mutations were homogeneous throughout several sections of the bilateral ovarian tumours and in omental metastases. These data confirm the findings of previous investigations describing TP53 mutation in ovarian carcinoma and demonstrate that archival paraffin-embedded tissues can be used for such analyses.lld:pubmed
pubmed-article:9301456pubmed:languageenglld:pubmed
pubmed-article:9301456pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9301456pubmed:citationSubsetIMlld:pubmed
pubmed-article:9301456pubmed:statusMEDLINElld:pubmed
pubmed-article:9301456pubmed:monthJullld:pubmed
pubmed-article:9301456pubmed:issn0959-8049lld:pubmed
pubmed-article:9301456pubmed:authorpubmed-author:MurphyMMlld:pubmed
pubmed-article:9301456pubmed:authorpubmed-author:TonerP GPGlld:pubmed
pubmed-article:9301456pubmed:authorpubmed-author:RussellS ESElld:pubmed
pubmed-article:9301456pubmed:authorpubmed-author:McManusD TDTlld:pubmed
pubmed-article:9301456pubmed:issnTypePrintlld:pubmed
pubmed-article:9301456pubmed:volume33lld:pubmed
pubmed-article:9301456pubmed:ownerNLMlld:pubmed
pubmed-article:9301456pubmed:authorsCompleteYlld:pubmed
pubmed-article:9301456pubmed:pagination1281-3lld:pubmed
pubmed-article:9301456pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9301456pubmed:meshHeadingpubmed-meshheading:9301456-...lld:pubmed
pubmed-article:9301456pubmed:meshHeadingpubmed-meshheading:9301456-...lld:pubmed
pubmed-article:9301456pubmed:meshHeadingpubmed-meshheading:9301456-...lld:pubmed
pubmed-article:9301456pubmed:meshHeadingpubmed-meshheading:9301456-...lld:pubmed
pubmed-article:9301456pubmed:meshHeadingpubmed-meshheading:9301456-...lld:pubmed
pubmed-article:9301456pubmed:meshHeadingpubmed-meshheading:9301456-...lld:pubmed
pubmed-article:9301456pubmed:meshHeadingpubmed-meshheading:9301456-...lld:pubmed
pubmed-article:9301456pubmed:year1997lld:pubmed
pubmed-article:9301456pubmed:articleTitleTP53 mutation in ovarian carcinoma.lld:pubmed
pubmed-article:9301456pubmed:affiliationDepartment of Medical Genetics, Queen's University of Belfast, U.K.lld:pubmed
pubmed-article:9301456pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9301456pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed